Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Price Target at $20.00

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has earned a consensus recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $20.00.

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley lifted their price target on Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th.

Contineum Therapeutics Stock Performance

Contineum Therapeutics stock opened at $13.86 on Friday. Contineum Therapeutics has a fifty-two week low of $5.07 and a fifty-two week high of $16.91. The stock has a market cap of $518.23 million, a PE ratio of -7.11 and a beta of 0.70. The firm’s 50-day simple moving average is $13.53 and its 200 day simple moving average is $13.50.

Contineum Therapeutics (NASDAQ:CTNM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.16. As a group, analysts predict that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Contineum Therapeutics

Several large investors have recently made changes to their positions in CTNM. Strs Ohio bought a new stake in shares of Contineum Therapeutics during the 1st quarter worth $27,000. China Universal Asset Management Co. Ltd. bought a new position in Contineum Therapeutics during the fourth quarter valued at about $43,000. Qube Research & Technologies Ltd purchased a new stake in Contineum Therapeutics during the second quarter worth about $43,000. Marex Group plc purchased a new stake in Contineum Therapeutics during the second quarter worth about $45,000. Finally, Royal Bank of Canada increased its holdings in Contineum Therapeutics by 73.5% during the first quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock worth $76,000 after buying an additional 2,454 shares during the last quarter.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.